Search results
- (-) Remove Press releases filter Press releases
Oxford BioMedica Announces a Strategic Alliance with Orchard Therapeutics
Oxford, UK & London, UK– 29 November 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene
Oxford BioMedica Notes Findings Reported by Novartis on CTL-019 at 58th American Society of Hematology Annual Meeting
Oxford, UK & London, UK– 5 December 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene
Oxford BioMedica Announces Publication of Pioneering RetinoStat® (OXB-201) Phase I Study Data in the Journal, Human Gene Therapy
-- RetinoStat® met its primary endpoint, demonstrating favourable safety and tolerability profiles
Oxford BioMedica Result of General Meeting and Directors Dealing
London, UK – 29 September 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell thera
Interim Results for the six months ended 30 June 2016
Oxford BioMedica plc
Interim Results for the six months ended 30 June 2016
Oxford BioMedica Announces MHRA GMP Manufacturing Approvals and Completion of Expansion Phase
- World-class centre for lentiviral gene therapy bioprocessing and process development approved and fully operational
Oxford BioMedica to Present at the Jefferies 2016 Healthcare Conference, New York
Oxford, UK – 6 June 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy grou
Establishment of a New Non-Exclusive LentiVector® Licence with MolMed
Oxford, UK – 7 June 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy grou
Oxford BioMedica and Green Cross LabCell form a Partnership to Develop Gene-modified NK Cell Therapeutics in cancer
Unique combination of Oxford BioMedica’s LentiVector® delivery platform and Green Cross LabCell’s NK cell platform to generate a pipeline o
Oxford BioMedica Appoints Corporate Broker
Oxford, UK – 17 May 2016: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy grou